Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

European Journal of Cancer

Volumn 43, Issue 14, 2007, Pages 2124-2133

  Tentori, Lucio ^a   Lacal, Pedro Miguel ^b   Muzi, Alessia ^a   Dorio, Annalisa Susanna ^a   Leonetti, Carlo ^c   Scarsella, Marco ^c   Ruffini, Federica ^b   Xu, Weizheng ^d   Min, Wokee ^e   Stoppacciaro, Antonella ^f   Colarossi, Cristina ^f   Wang, Zhao Qi ^e   Zhang, Jie ^d   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d MGI Pharma   (United States)

^e FRITZ LIPMANN INSTITUTE   (Germany)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Anti angiogenic compounds; Endothelial cells; PARP inhibitors; Poly(ADP ribose) polymerase

Indexed keywords

10 (4 METHYL PIPERAZIN 1 YLMETHYL) 2H 7 OXA 1,2 DIAZABENZO[DE]ANTHRACEN 3 ONE; GPI 15427; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG RECEPTOR BINDING; ENDOTHELIUM; ENZYME INHIBITION; GENE DELETION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MIGRATION INHIBITION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE DELETION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; TUBULIN MODULATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548514842     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.010     Document Type: Article

References (33)

1. Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. BioEssays 23 (2001) 795-806
2. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 (2002) 375-429
3. Tentori L., and Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52 (2005) 25-33
4. Tentori L., Leonetti C., Scarsella M., et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing haematologic malignancy at the central nervous system site. Blood 99 (2002) 2241-2244
5. Tentori L., Leonetti C., Scarsella M., et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9 (2003) 5370-5379
6. Tentori L., Leonetti C., Scarsella M., et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumours. Int J Oncol 26 (2005) 415-422
7. Tentori L., Leonetti C., Scarsella M., et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 20 (2006) 1709-1711
8. Veuger S.J., Curtin N.J., Smith G.C., and Durkacz B.W. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 23 (2004) 7322-7329
9. Miknyoczki S.J., Jones-Bolin S., Pritchard S., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2 (2003) 371-382
10. Malanga M., and Althaus F.R. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 279 (2004) 5244-5248
11. Plummer E.R. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6 (2006) 364-368
12. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 52 (2005) 109-118
13. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
14. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
15. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66 (2006) 8109-8115
16. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
17. Robinson S.C., and Coussens L.M. Soluble mediators of inflammation during tumour development. Adv Cancer Res 93 (2005) 159-187
18. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol Res 52 (2005) 72-82
19. Martin-Oliva D., Aguilar-Quesada R., O'valle F., et al. Inhibition of poly(ADP-ribose) polymerase modulates tumour-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66 (2006) 5744-5756
20. Rajesh M., Mukhopadhyay P., Godlewski G., et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun 350 (2006) 1056-1062
21. Rajesh M., Mukhopadhyay P., Batkai S., et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun 350 (2006) 352-357
22. Tentori L., Vergati M., Muzi A., et al. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int J Oncol 27 (2005) 525-535
23. Krump-Konvalinkova V., Bittinger F., Unger R.E., Peters K., Lehr H.A., and Kirkpatrick C.J. Generation of human pulmonary microvascular endothelial cell lines. Lab Invest 81 (2001) 1717-1727
24. Wang Z.-Q., Auer B., Stingl L., et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9 (1995) 509-520
25. Pacher P., Liaudet L., Bai P., et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300 (2002) 862-867
26. Racz I., Tory K., Gallyas Jr. F., et al. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumour activity. Biochem Pharmacol 63 (2002) 1099-1111
27. Pacher P., Liaudet L., Mabley J.G., Cziraki A., Hask G., and Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 17 (2006) 369-375
28. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9 (2003) 677-684
29. Beckert S., Farrahi F., Perveen Ghani Q., et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem Biophys Res Commun 341 (2006) 67-72
30. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 28 (2003) 488-494
31. Li B., Sharpe E.E., Maupin A.B., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumour neovascularization. FASEB J 20 (2006) 1495-1497
32. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
33. Kraus W.L., and Lis J.T. PARP goes transcription. Cell 113 (2003) 677-683